Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 09'th May 2024
SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates an
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
06:56pm, Friday, 03'rd May 2024
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 02'nd May 2024
Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
08:00am, Thursday, 02'nd May 2024
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide bu
Recursion to Participate in Upcoming Investor Conferences
08:01am, Wednesday, 01'st May 2024
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation
Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves
08:58am, Saturday, 27'th Apr 2024
Nvidia's equity portfolio ballooned beyond $100 million in the fourth quarter, requiring public disclosures. Just two stocks make up nearly all of its portfolio.
The Top 3 Biotech Stocks to Buy in April 2024
07:00am, Saturday, 27'th Apr 2024
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
06:56pm, Thursday, 25'th Apr 2024
Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.
3 Millionaire-Maker Biotech Stocks
10:30am, Thursday, 25'th Apr 2024
Oncology's future prominently features the kind of autoimmune R&D work that Iovance is doing. Helped by new technology, Recursion is using artificial intelligence to develop new drugs.
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
09:02pm, Sunday, 21'st Apr 2024
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent
Where Will Recursion Pharmaceuticals Be in 5 Years?
07:00am, Wednesday, 17'th Apr 2024
By 2029, Recursion Pharmaceuticals could have multiple products. There is also a chance it could be facing some serious challenges.
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
08:00am, Tuesday, 16'th Apr 2024
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan,
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
12:54pm, Monday, 15'th Apr 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
05:50am, Wednesday, 10'th Apr 2024
Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good.
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
08:45am, Thursday, 04'th Apr 2024
Recursion Pharmaceuticals' approach to developing drugs is ambitious. But the company has yet to produce the kinds of results investors want.
